Lundbeck-backed Iconic Therapeutics, which aims to apply tissue factor biology to retinal disease and cancer treatments, has now raised $80m altogether.
US-based biopharmaceutical company Iconic Therapeutics closed a series C round featuring pharmaceutical firm Lundbeck at $48.5m yesterday after raising an additional $10m.
Lundbeckfond Ventures, the venture capital fund sponsored by Lundbeck, was among the investors in the round’s initial tranche, which closed in January this year, investing alongside HBM Healthcare Investments, Cormorant Asset Management, Osage University Partners, MPM Capital and H.I.G. Capital.
Xeraya Capital, a private equity and venture capital investor backed by the Malaysian government, was among the…
